Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy

Schwarzenberg, J. von; Czernin, Johannes; Cloughesy, Timothy F.; Ellingson, Benjamin M.; Pope, Whitney B.; Grogan, Tristan; Elashoff, David; Geist, Cheri; Silverman, Daniel; Phelps, Michael E.; Chen, Wei

doi:10.1158/1078-0432.ccr-13-1440

Cited by 124 publications

(106 citation statements)

References 34 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Excellent results with FDOPA PET were also reported regarding the monitoring of antiangiogenic treatement [14] and for the differentiation of recurrent brain metastases from radiation-induced changes [15].…”

Section: To the Editormentioning

confidence: 96%

Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]

Langen

Tonn²,

Weller

et al. 2014

J Neurooncol

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 96%

Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]

Langen

Tonn²,

Weller

et al. 2014

J Neurooncol

View full text Add to dashboard Cite

“…Treatment response and outcome in bevacizumab therapy has been suggested to be better assessed by 18 F-FET and 18 F-FDOPA, compared to MRI (6,(74)(75)(76)(77). Also, reliable monitoring of TMZ and nitrosourea-based chemotherapy effects has been demonstrated in patients with recurrent HGG (9,31,64,66,70,71).…”

Section: Amino-acid Petmentioning

confidence: 99%

PET for Therapy Response Assessment in Glioblastoma

et al. 2017

View full text Add to dashboard Cite

Glioblastoma (GB) is the most malignant and the most common type of glioma in adults, accounting for 60-70% of all malignant gliomas. Despite the current therapy, the clinical course of GB is usually rapid, with a mean survival time of approximately 1 year. For therapy response assessment in GB, magnetic resonance imaging (MRI) is the method of choice. In 2010, the Response Assessment in Neuro-Oncology (RANO) was introduced, including the tumor size (in 2D) as measured on T2-weighted and Fluid Attenuated Inversion Recovery (FLAIR)-weighted images, in addition to the contrast-enhancing tumor part. Although the RANO criteria addressed some of the limitations of the previous MacDonald criteria for therapy evaluation in high-grade glioma, treatment-related side effects hamper correct response assessment. To address the above-mentioned drawbacks in the follow-up of GB, incorporating changes in tumor biology measured by advanced MRI and positron emission tomography (PET) imaging, which may precede anatomical changes of the tumor volume, is promising. Imaging biomarkers capable of predicting response at an early time point after treatment initiation are the premise of personalized treatment enabling change or GB Treatment Response Using PET 176 discontinuation of therapy to prevent ineffective treatment or adverse events of treatment. In this chapter, an overview of applicable PET tracers for the therapy response assessment in GB and the determination of tumor recurrence versus treatment-related effects is given.

show abstract

“…Many studies have shown that amino acid PET provides information complementary to that provided by MR imaging (23,24). Examples include better definition of the infiltration of normal brain by gliomas (25), differentiation of recurrent disease from treatment-related changes (26), assessment of the tumor response to therapy (27), and prediction of the prognosis for patients with low-grade tumors (28,29). Although PET and MR imaging studies of the brain can easily be fused retrospectively, the simultaneous acquisition of PET and MR imaging studies will further improve the coregistration of PET and MR imaging information.…”

Section: Limited Number Of Overlapping Clinical Indications For 18 F-mentioning

confidence: 99%

PET/MR Imaging: A Critical Appraisal

Weber

2014

J Nucl Med

View full text Add to dashboard Cite

Despite considerable excitement about the potential of PET/MR imaging for the detection, staging, and functional characterization of cancer, this new technology is evolving significantly more slowly than PET/CT. This slower evolution is due partly to ongoing technologic challenges (e.g., accurate attenuation correction of PET images) but also to the complex logistics of combining a whole-body PET scan with whole-body or organ-specific MR imaging. Most PET/MR imaging research published so far has focused on cancer staging and restaging in patients undergoing 18 F-FDG PET/CT as the standard of care. These studies have demonstrated the feasibility of clinical 18 F-FDG PET/MR imaging but so far have not shown substantial improvements in staging. This situation may not be unexpected in view of the fact that MR imaging has not replaced CT for staging of the malignancies for which 18 F-FDG PET/CT is most commonly used. Given the widespread concerns about rising health care costs in general and the costs of advanced imaging techniques in particular, establishing 18 F-FDG PET/MR imaging for whole-body cancer staging may be challenging because it requires more expensive equipment and longer acquisition times than 18 F-FDG PET/CT. An alternative approach to developing clinical PET/MR imaging is to study how stand-alone, organ-specific MR imaging can be improved by PET/MR imaging. Unfortunately, however, 18 F-FDG PET has significant limitations for the tumors that are most commonly studied with MR imaging (brain, liver, pancreatic, and prostate tumors). However, this situation may change with the development of new radiopharmaceuticals, such as prostate-specific membrane or gastrin-releasing peptide receptor ligands for the imaging of prostate cancer. In conclusion, PET/MR imaging has many potential advantages over PET/CT (lower radiation exposure, higher soft-tissue contrast, and multiparametric imaging). Realizing this potential in clinics likely will require new radiopharmaceuticals and applications other than whole-body cancer staging.

show abstract

Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy

Cited by 124 publications

References 34 publications

Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]

Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]

PET for Therapy Response Assessment in Glioblastoma

PET/MR Imaging: A Critical Appraisal

Contact Info

Product

Resources

About